Philip T Cagle
Overview
Explore the profile of Philip T Cagle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
2843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anand K, Phung T, Bernicker E, Cagle P, Olsen R, Thomas J
Clin Lung Cancer
. 2020 Jul;
21(5):437-442.
PMID: 32600793
Introduction: In order to standardize and expedite molecular biomarker testing, we implemented reflex ordered testing of targeted gene alterations in newly diagnosed lung adenocarcinomas within our hospital system. Patients And...
2.
Hariri L, Smith M, Mino-Kenudson M, Allen T, Attanoos R, Borczuk A, et al.
Ann Am Thorac Soc
. 2020 Jan;
17(5):550-554.
PMID: 31945306
No abstract available.
3.
Funkhouser Jr W, Hayes D, Moore D, Funkhouser 3rd W, Fine J, Jo H, et al.
Arch Pathol Lab Med
. 2018 May;
142(12):1537-1548.
PMID: 29708428
Context.—: Measurement of interpathologist diagnostic agreement (IPDA) should allow pathologists to improve current diagnostic criteria and disease classifications. Objectives.—: To determine how IPDA for pathologists' diagnoses of non-small cell lung...
4.
Monroig-Bosque P, Driver B, Morales-Rosado J, Deavers M, Tacha D, Bernicker E, et al.
Arch Pathol Lab Med
. 2018 Feb;
142(11):1388-1393.
PMID: 29431467
Context.—: The interaction between programmed death ligand-1 (PD-L1) and programmed death receptor-1 (PD-1) on activated T cells sends an inhibitory signal that dampens the immune response. Tumors can express PD-L1...
5.
Lindeman N, Cagle P, Aisner D, Arcila M, Beasley M, Bernicker E, et al.
J Mol Diagn
. 2018 Feb;
20(2):129-159.
PMID: 29398453
Context: In 2013, an evidence-based guideline was published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology to...
6.
Lindeman N, Cagle P, Aisner D, Arcila M, Beasley M, Bernicker E, et al.
J Thorac Oncol
. 2018 Feb;
13(3):323-358.
PMID: 29396253
Context: In 2013, an evidence-based guideline was published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology to...
7.
Lindeman N, Cagle P, Aisner D, Arcila M, Beasley M, Bernicker E, et al.
Arch Pathol Lab Med
. 2018 Jan;
142(3):321-346.
PMID: 29355391
Context: - In 2013, an evidence-based guideline was published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology...
8.
Nakhleh R, Fitzgibbons P, Washington M, Baker T, Berman M, Cagle P
Arch Pathol Lab Med
. 2017 Nov;
142(2):161.
PMID: 29166144
No abstract available.
9.
Driver B, Miller R, Miller T, Deavers M, Gorman B, Mody D, et al.
Arch Pathol Lab Med
. 2017 Aug;
141(11):1529-1532.
PMID: 28829153
Context: - Programmed death ligand-1 (PD-L1) expression in non-small cell lung carcinoma (NSCLC) is heterogeneous and known to be underestimated on small biopsies. Correlation of PD-L1 expression with clinicopathologic features...
10.
Thunnissen E, Allen T, Adam J, Aisner D, Beasley M, Borczuk A, et al.
Arch Pathol Lab Med
. 2017 Jul;
142(3):408-419.
PMID: 28686497
The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and...